Skip to main content

Distinguished Speaker Series | Vsevolod V. Gurevich, PhD

-
Location
https://ucihealth.zoom.us/j/92801383742?pwd=vfI4WBKGwibdfbtyznYWvAbSg3CccO.1
Event Type

Add to Calendar: Outlook | Google | iCal

The Center for Translational Vision Research Distinguished Speaker Series, also known as "Friday Seminars" showcases innovative research across the world. The seminar series has now been expanded to include lectures by experts on topics ranging from Ophthalmology, Genetics, Biochemistry, Neurobiology, Imaging, Computational Sciences to Novel Ophthalmic Treatments.

All talks are hybrid. You can join us in person at

The Falling Leaves Foundation Building, Main Entrance Level

Conference Room (2nd Floor by signage)

847 Health Sciences Quad

You can also join us by zoom. Zoom link and information are on your right and in the calendar links above.

April 10, 2026 | Vsevolod V. Gurevich, PhD

Arrestins: deceptive beauty of structures

 

Learn More About the Distinguished Speaker Series

Featured


Vsevolod V. Gurevich, PhD
Vsevolod V. Gurevich, PhD
  • Vsevolod V. Gurevich, PhD, Cornelius Vanderbilt Chair; Professor of Pharmacology; Professor of Ophthalmology and Visual Sciences, Vanderbilt University

Vsevolod V. Gurevich, PhD, is the Cornelius Vanderbilt Endowed Chair and Professor of Pharmacology and Ophthalmology and Visual Sciences at Vanderbilt University. His research focuses on the structure and function of arrestin proteins, critical regulators of G protein-coupled receptor (GPCR) signaling that control receptor desensitization, internalization, and downstream signaling pathways. His laboratory has determined the crystal structures of all four vertebrate arrestin subtypes and investigates how arrestins selectively bind activated receptors and scaffold distinct signaling cascades, including MAP kinase pathways. Using a multidisciplinary approach that integrates structural biology, biochemistry, molecular pharmacology, and cell biology, Dr. Gurevich’s team seeks to engineer “designer” or phosphorylation-independent arrestins capable of precisely directing cellular signaling, with potential applications in treating retinal disorders, cancer, and other diseases linked to dysregulated GPCR signaling.